Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMSPN58)

Drug Name
Clomethiazole Drug Info
Synonyms
Clomethiazole; 533-45-9; Chlormethiazole; 5-(2-CHLOROETHYL)-4-METHYLTHIAZOLE; Distraneurin; Emineurina; Clomethiazolum; Chlormethiazol; Chlorethiazol; Chlorethiazole; Somnevrin; Clometiazole; Clomethiazol; 5-(2-Chloroethyl)-4-methyl-1,3-thiazole; Thiazole, 5-(2-chloroethyl)-4-methyl-; Clometiazolo [DCIT]; Chloro-S.C.T.Z.; C6H8ClNS; UNII-0C5DBZ19HV; Clometiazol [INN-Spanish]; Clomethiazolum [INN-Latin]; WY 1485; Clomethiazole [INN]; SCTZ [as edisylate]; EINECS 208-565-7; 4-Methyl-5-(beta-chloroethyl)thiazole; BRN 0114244; 0C5DBZ19HV
Cross-matching ID
PubChem CID
10783
ChEBI ID
CHEMBL92875
CAS Number
CAS 533-45-9
TTD Drug ID
D0G3LM
INTEDE Drug ID
DR0348

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Fatty acid degradation 2.22 0.00e+0 40/43 (93.02%) ADH1B;ECI2;ACAA2;...
Complement and coagulation cascades 2.17 0.00e+0 76/85 (89.41%) SERPINA1;TFPI;CPB2;...
DNA replication 2.15 0.00e+0 34/36 (94.44%) PCNA;POLE2;RFC3;...
Fat digestion and absorption 2.05 2.00e-3 35/43 (81.4%) CD36;APOA1;APOB;...
Fanconi anemia pathway 2.00 3.20e-3 36/54 (66.67%) MLH1;CENPX;RMI1;...
Drug metabolism 1.99 2.67e-3 78/151 (51.66%) ADH1B;FMO3;UGT2B4;...
Retinol metabolism 1.95 2.29e-3 41/68 (60.29%) ADH1B;UGT2B4;ADH1A;...
PPAR signaling pathway 1.87 6.00e-3 66/74 (89.19%) FABP4;CD36;FABP7;...
Ascorbate and aldarate metabolism 1.85 6.22e-3 15/30 (50%) UGT2B4;UGT2A3;UGT2B28;...
Steroid hormone biosynthesis 1.85 5.60e-3 43/61 (70.49%) UGT2B4;AKR1C3;CYP2E1;...
Linoleic acid metabolism 1.84 6.55e-3 21/29 (72.41%) CYP2E1;CYP2C8;PLA2G4C;...
Porphyrin and chlorophyll metabolism 1.83 7.33e-3 23/43 (53.49%) UGT2B4;CP;UGT2A3;...
Mismatch repair 1.81 8.00e-3 22/23 (95.65%) PCNA;RFC3;MLH1;...
Bile secretion 1.80 9.14e-3 68/90 (75.56%) CA2;UGT2B4;ABCB4;...
Nucleotide excision repair 1.79 9.07e-3 40/47 (85.11%) PCNA;POLE2;RFC3;...
Metabolism of xenobiotics by cytochrome P450 1.74 1.15e-2 49/77 (63.64%) ADH1B;UGT2B4;SULT2A1;...
Pyruvate metabolism 1.74 1.27e-2 41/47 (87.23%) ADH1B;DLD;ADH1A;...
Base excision repair 1.71 1.56e-2 29/33 (87.88%) PCNA;POLE2;FEN1;...
Homologous recombination 1.70 1.52e-2 35/41 (85.37%) BARD1;MRE11;SSBP1;...
Primary bile acid biosynthesis 1.68 2.32e-2 15/17 (88.24%) AKR1C4;CYP7A1;CYP46A1;...
alpha-Linolenic acid metabolism 1.66 2.51e-2 17/25 (68%) PLA2G4C;PLA2G10;PLA2G2A;...
Valine, leucine and isoleucine degradation 1.65 2.55e-2 42/48 (87.5%) ABAT;ACAA2;DLD;...
Cardiac muscle contraction 1.60 3.86e-2 64/87 (73.56%) MYL2;TPM3;ATP2A1;...
Glycerophospholipid metabolism 1.59 4.40e-2 71/98 (72.45%) CHPT1;ETNK1;PLA2G4C;...
Cholesterol metabolism 1.58 4.42e-2 44/50 (88%) CD36;LPL;APOA1;...
Cell cycle 1.57 4.74e-2 110/124 (88.71%) E2F2;CDC20;PCNA;...
Herpes simplex virus 1 infection -1.60 4.87e-2 165/498 (33.13%) PIK3CB;BCL2;CYCS;...
Adherens junction -1.60 4.75e-2 63/71 (88.73%) ACP1;TJP1;SORBS1;...
Fluid shear stress and atherosclerosis -1.61 4.45e-2 123/139 (88.49%) MAP2K6;GSTM1;SUMO4;...
IL-17 signaling pathway -1.62 4.31e-2 84/94 (89.36%) MAPK14;CCL11;CSF2;...
Platelet activation -1.62 4.48e-2 106/124 (85.48%) PLCB2;MAPK3;PTGIR;...
Influenza A -1.62 4.56e-2 156/172 (90.7%) HLA-DOA;MYD88;IRF7;...
Neutrophil extracellular trap formation -1.64 4.45e-2 101/189 (53.44%) HDAC5;SELP;VDAC2;...
Rheumatoid arthritis -1.64 4.39e-2 78/93 (83.87%) CD86;ATP6V1E1;CSF2;...
Allograft rejection -1.66 4.37e-2 32/38 (84.21%) FAS;CD86;HLA-DRB1;...
Asthma -1.66 4.52e-2 25/31 (80.65%) CCL11;HLA-DRB1;HLA-DQA1;...
Yersinia infection -1.68 4.04e-2 120/137 (87.59%) MYD88;TAB2;MAPK3;...
Sphingolipid metabolism -1.69 4.12e-2 32/49 (65.31%) SMPD3;B4GALT6;ASAH1;...
Leukocyte transendothelial migration -1.69 4.22e-2 90/114 (78.95%) CLDN16;ITGB1;CD99;...
Endocytosis -1.70 3.70e-2 198/252 (78.57%) RAB11FIP5;GRK6;IL2RG;...
Growth hormone synthesis, secretion and action -1.70 3.93e-2 108/119 (90.76%) ADCY9;STAT5B;GNAI3;...
Staphylococcus aureus infection -1.70 4.12e-2 72/95 (75.79%) PTAFR;KRT9;HLA-DOA;...
Pathogenic Escherichia coli infection -1.71 4.33e-2 152/197 (77.16%) CLDN15;MYD88;TAB2;...
Toxoplasmosis -1.74 3.65e-2 103/112 (91.96%) HLA-DOA;MYD88;GNAI3;...
Shigellosis -1.76 3.17e-2 180/246 (73.17%) FBXW11;MYD88;CAPN2;...
Proteoglycans in cancer -1.79 2.48e-2 172/205 (83.9%) ARHGEF12;FZD5;ITGB1;...
Synaptic vesicle cycle -1.81 2.14e-2 63/78 (80.77%) SLC6A2;SLC18A2;CLTB;...
Tuberculosis -1.81 2.37e-2 159/180 (88.33%) ATP6V0D1;ARHGEF12;STAT1;...
Osteoclast differentiation -1.85 1.19e-2 117/127 (92.13%) TAB2;PPP3CB;MAPK3;...
Steroid biosynthesis -1.85 1.19e-2 19/20 (95%) NSDHL;HSD17B7;SQLE;...
Transcriptional misregulation in cancer -1.88 9.89e-3 158/192 (82.29%) LYL1;FUS;RXRB;...
Bacterial invasion of epithelial cells -1.91 9.50e-3 59/77 (76.62%) CLTB;DOCK1;GAB1;...
Leishmaniasis -2.00 2.97e-3 67/77 (87.01%) CR1;NCF2;HLA-DOA;...
Antigen processing and presentation -2.03 0.00e+0 60/78 (76.92%) KIR2DS4;CTSL;CTSS;...
Type I diabetes mellitus -2.12 0.00e+0 38/43 (88.37%) CD86;HLA-DRB1;IL1A;...
Graft-versus-host disease -2.23 0.00e+0 32/42 (76.19%) FAS;CD86;HLA-DRB1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H